Search Results
Your search for it matches 16118 pages
Showing 3851 - 3900Expert Point of View: Steven J. Chmura, MD, PhD
At a press conference at the 2021 ASTRO Annual Meeting, Steven J. Chmura, MD, PhD, Professor of Radiation Oncology and Scientific Director of the Cancer Clinical Trials Office, University of Chicago, commented on the CURB study results. “Most trials of stereotactic body radiation therapy (SBRT)...
Can SBRT to Selected Sites of Limited Progression or Oligoprogression Extend Progression-Free Survival in Advanced Lung Cancer but Not Breast Cancer?
Stereotactic body radiation therapy (SBRT) lengthens progression-free survival for patients with advanced lung cancer who have oligoprogression (ie, tumors that have not been fully responsive to systemic chemotherapy or immunotherapy), according to an interim analysis of the CURB oligoprogression...
Expert Point of View: Elizabeth Nichols, MD
Invited discussant Elizabeth Nichols, MD, of the University of Maryland, School of Medicine, Baltimore, commented on both the phase II TRIUMPH-T and the phase III MC1635 trials. “There are multiple techniques in use for accelerated partial breast irradiation. Optimal dose and fractionation are...
Durable Responses in Metastatic NSCLC: Are We Getting Closer to a Cure?
In the United States, the incidence-based mortality related to non–small cell lung cancer (NSCLC) has decreased by approximately 3% each year since 2008 in men; during the same period, the mortality in women decreased by 2% to 4% annually.1 Although multiple factors are likely responsible for the...
From Cancer Survivor to Citizen Astronaut
When I was diagnosed with osteosarcoma of my left femur nearly 20 years ago, I remember telling my parents that I didn’t want to die. The diagnosis was terrifying because all the people I knew who had cancer had passed away, and I thought this cancer would kill me, too. That evening, my dad went...
Shorter-Course Radiation Therapy: A New Practice Standard After Prostatectomy?
Hypofractionated radiotherapy to the prostate bed proved to be noninferior to conventionally fractionated radiotherapy after prostatectomy regarding gastrointestinal and genitourinary side effects, according to the results of the phase III NRG Oncology GU003 trial, presented at the 2021 American...
Novel Therapies Under Study in Acute Myeloid Leukemia
Newly identified genetic abnormalities in AML have led to novel therapies that can target some of them, as the landscape for treatment continues to evolve. During the 2021 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies, Alice S. Mims MD, presented updates in...
Early Study Examines Potential Benefits of a Fasting-Mimicking Diet in Patients With Cancer
A severely calorie-restricted, low-carbohydrate, low-protein, 5-day dietary regimen that mimics fasting was shown to be safe and feasible, and it resulted in a decrease of blood glucose and growth factor concentration, a reduction in peripheral blood immunosuppressive cells, and enhanced intratumor ...
Exercise Program May Help to Reduce Upper Limb Disability After Breast Cancer Surgery
Arm and shoulder disability and pain that some women who have had breast cancer surgery experience as a side effect of their procedure may be reduced by following a physiotherapy-led exercise program, according to a new study published by Bruce et al in The BMJ. The report showed an improvement in...
Newer Agents on the Horizon for Refractory or Relapsed DLBCL
Although treating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains challenging, some newer therapies on the horizon offer promise, including bispecific antibodies, anti-CD47 antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapy,...
2021 State of Lung Cancer Report Finds Survival Has Increased but Remains Significantly Lower for People of Color
The new 2021 State of Lung Cancer report reveals that the 5-year survival rate for lung cancer increased from 14.5% nationally to 23.7%, yet it remains significantly lower among communities of color. The American Lung Association’s fourth annual report also highlights how the toll of lung cancer...
Model May Help Identify Subtypes of Multiple Myeloma
Researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for subtypes of multiple myeloma. They also identified potential targeted treatments based on the findings, which were reported by...
FDA Expands Eligibility for COVID-19 Vaccine Boosters
On November 19, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals aged 18 years and older after completion of primary vaccination with any ...
Study Examines Availability of All-Trans Retinoic Acid in U.S. Hospitals
New research published by Geer et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that fewer than one-third of hospitals in the United States had immediate availability of all-trans retinoic acid (ATRA), a crucial blood cancer medication. ATRA is initiated early in the...
Digital Symptom Monitoring System May Improve Patients’ Symptom Control and Physical Function During Cancer Therapy
A digital symptom monitoring system in which patients undergoing cancer treatment could report symptoms through weekly at-home surveys resulted in better symptom control and physical function, as well as improved communication with their medical team, according to results from a study by Basch et...
Thomas Gruenberger, MD, Shares Thoughts on Radiotherapy for Colorectal Liver Metastases
Invited discussant of the phase III EPOCH trial, Thomas Gruenberger, MD, a surgical oncologist at the Clinic Favoriten, Health Network Vienna, noted that the trial’s “intention was fulfilled,” thus making it the “first positive phase III trial that prolonged both progression-free and hepatic...
Incidence of Pancreatic Cancer in the United States by Age and Sex, 2000–2018
In a study reported in a research letter in JAMA, Gaddam et al found that the incidence of pancreatic cancer has increased in both men and women between 2000 and 2018, with a greater relative increase being observed in younger women. Pancreatic cancer incidence rates per 100,000 population...
Study Explores Method to Selectively Grow Tumor-Targeting T Cells for Cancer Therapy
A preclinical study published by Arnaud et al in Nature Biotechnology has demonstrated the utility and efficacy of a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens and destroy the tumors that express them. Developed by a team of...
FDA Approves Ropeginterferon alfa-2b-njft for Adults With Polycythemia Vera
The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adults with polycythemia vera. The new agent is a monopegylated, long-acting interferon, which exhibits its cellular effects in polycythemia vera in the bone marrow. Ropeginterferon...
Use of Genomic Classifier Score May Help to Personalize Therapy for Men With High-Risk Prostate Cancer
A 22-genomic classifier (the Decipher score) was able to predict the course of disease in men with high-risk prostate cancer, according to a patient-level meta-analysis of three randomized clinical trials presented at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 Use of...
Novel Drug Combination May Help Children With Acute Promyelocytic Leukemia Avoid Conventional Chemotherapy
A clinical trial recently published by Kutny et al in JAMA Oncology found that the combination of all-trans retinoic acid and arsenic trioxide was highly effective in children with standard- and high-risk acute promyelocytic leukemia (APL). Nearly all patients in the trial survived for 2 years...
Study Examines Immunotherapy Outcomes in Patients With Solid Tumors Who Are Ineligible for Clinical Trials
Patients with solid tumors who are ineligible for clinical trials receive immune checkpoint inhibitors at greater rates than patients who are eligible, despite no survival benefit, according to a recent study by researchers at the Perelman School of Medicine at the University of Pennsylvania. The...
President Biden Nominates Robert M. Califf, MD, MACC, as FDA Commissioner
President Joseph Biden has nominated Robert M. Califf, MD, MACC, for the position of Commissioner of the U.S. Food and Drug Administration (FDA). Dr. Califf is an internationally recognized expert in clinical trial research, health disparities, health-care quality, and cardiovascular medicine....
Effect of National HPV Vaccination Program on the Incidence of Cervical Cancer and Intraepithelial Neoplasia in Young Women in England
As reported in The Lancet by Falcaro et al, a register-based observational study has shown that the England national human papillomavirus (HPV) vaccine program, initiated in 2008 using a bivalent vaccine (Cervarix; HPV16/18), has been successful in reducing the rates of cervical cancer and grade 3...
NCI-Designated Cancer Center Compliance With CMS Price Transparency Rules
In a cross-sectional analysis reported in a research letter in JAMA Oncology, Chino et al found that a minority of National Cancer Institute (NCI)-designated cancer centers (NCI-CCs) were fully compliant with Centers for Medicare & Medicaid Services (CMS) price transparency rules. Study ...
De-escalation of Radiation Therapy for HPV-Positive, Intermediate-Risk Oropharyngeal Cancer
De-escalated adjuvant radiotherapy appears to be safe in patients with surgically resectable, human papillomavirus (HPV)--positive oropharyngeal cancers, particularly in patients without extranodal extension or pN2 disease by American Joint Committee on Cancer (AJCC) 8th edition. These findings...
Expert Point of View: Sophia C. Kamran, MD
Sophia C. Kamran, MD, a radiation oncologist at Massachusetts General Hospital and Assistant Professor of Radiation Oncology at Harvard Medical School, who was not involved in the RTOG 0815 study, commented: “The results of RTOG 0815 demonstrate that in the setting of contemporary dose-escalated...
No Survival Benefit but Improved Secondary Endpoints With Radiotherapy Plus Androgen Suppression in Intermediate-Risk Prostate Cancer
Both dose-escalated radiation therapy and short-course androgen-deprivation therapy have been shown to improve outcomes in intermediate-risk prostate cancer, but it is not clear whether giving both modalities upfront to newly diagnosed patients is of benefit. The phase III RTOG 0815 study presented ...
Study Examines COVID-19 Outcomes in Pediatric Patients With Cancer
Most children and adolescents with cancer have mild COVID-19 disease and make a full recovery, a new study by Haeusler et al in the European Journal of Cancer has found. But pediatric patients with cancer and underlying health conditions, severe infections, and low white blood cell counts were...
International Conference Updates Guidelines for Advanced Breast Cancer
Patients with two out of the three most common types of advanced breast cancer now have an average survival time of at least 5 years, according to a panel of experts at the Advanced Breast Cancer Sixth International Consensus Conference (ABC6), which was held virtually this year. The Advanced...
Second Surprise Billing Rule Covers Dispute Resolution Processes, Good Faith Estimates for the Uninsured
On September 30, 2021, the U.S. Department of Health and Human Services (HHS), the Department of Labor, and the Department of the Treasury (“the Departments”), along with the Office of Personnel Management, released an interim final rule with comment period, entitled “Requirements Related to...
Showcasing 50 Years of Advances in Cancer Research and Treatment
The AACR Cancer Progress Report 2021, published on October 13, celebrates the gains made in cancer research since President Richard Nixon signed the National Cancer Act into law on December 23, 1971, especially against such life-threatening cancers as metastatic melanoma and lung cancer.1 The...
Living in Survival Mode
About 10 years ago, on a flight to Detroit, while returning from the San Antonio Breast Cancer Symposium, I had a conversation with Lori Pierce, MD, FASTRO, FASCO, radiation oncologist at the University of Michigan, who went on to become ASCO President for the 2020–2021 term. I recall inviting her...
David Morse Livingston, MD, Scientist and Esteemed Mentor, Dies at 80
David Morse Livingston, MD, formerly the Charles A. Dana Chair in Human Cancer Genetics at Dana-Farber and the Emil Frei III Distinguished Professor of Medicine at Harvard Medical School, died unexpectedly on October 17, 2021. He was Deputy Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) ...
Expert Point of View: Monica Arnedos, MD, PhD
The invited discussant of BrighTNess,1 Monica Arnedos, MD, PhD, Head of the Breast Cancer Research Program at the Institut Bergonié in Bordeaux, France, said the findings add to growing support for using carboplatin in triple-negative breast cancer, but their clinical application could be...
BrighTNess: Neoadjuvant Carboplatin Improves Event-Free Survival in Triple-Negative Breast Cancer
In patients with early resectable triple-negative breast cancer, not only did the addition of carboplatin to standard neoadjuvant chemotherapy improve pathologic complete response rates, it also improved 4-year event-free survival, regardless of BRCA status, according to the latest analysis of the...
Pamela Kunz, MD, Named 2021 Woman Oncologist of the Year
Women Leaders in Oncology has named Pamela Kunz, MD, the 2021 Woman Oncologist of the Year. Dr. Kunz is Associate Professor of Medicine (Medical Oncology), Director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, Chief of GI Medical Oncology, and Vice...
Many Patients With Solid Tumors Mount an Adequate Response to SARS–CoV-2 Vaccine, Dutch Study Reports
Individuals with solid tumors had an appropriate, protective immune response to vaccination against SARS–CoV-2, at least with the mRNA-1273 vaccine, and side effects were no more common than in the general population, according to a large Dutch study.1 The study was reported during the European...
Expert Point of View: Michaela A. Dinan, PhD
Invited discussant of the study on medication nonadherence, Michaela A. Dinan, PhD, Co-Leader of Cancer Prevention and Control at Yale Cancer Center and Associate Professor of Chronic Disease Epidemiology at the Yale School of Public Health, in Connecticut, noted that the CAHPS survey data provide...
WHO Director-General Grants Posthumous Award to Henrietta Lacks
World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, MD, honored the late Henrietta Lacks with a WHO Director-General’s award, recognizing her world-changing legacy. Ms. Lacks, a Black American woman, died of cervical cancer 70 years ago, on October 4, 1951. While she...
The Worst Part of Having Cancer Was the Guilt
When I was diagnosed with small cell lung cancer in 1992, at age 38, I remember thinking, “I wish I had breast cancer.” Breast cancer elicits such sympathy from people. A diagnosis of small cell lung cancer mainly gets you stern looks of disapproval and disappointment. There is so much stigma...
Cancer Researcher and Drug Developer, Joseph R. Bertino, MD, Dies at 91
Over the arc of his notable career, Joseph R. Bertino, MD, garnered many honors for his scientific contributions leading to curative treatments for leukemia and lymphoma, such as ASCO’s David A. Karnofsky Award. Yet his legacy was perhaps most prominently punctuated by the multitude of patients...
AML Pioneer and ‘Gentle Soul,’ Elihu H. Estey, MD, Dies at 75
“A lot of times, younger bright physicians are afraid to say what they really think, out of fear of challenging the dogma. One of the things I do when mentoring is to ask why we are doing a particular therapy or intervention. I tell my mentees not to let the data interfere with your knowledge,”...
Early Experiences in the United States Helped Shape an International Oncology Career for Aleix Prat, MD, PhD
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Aleix Prat, MD, PhD, Head of the Medical Oncology Department, Hospital Clinic of Barcelona. Dr. Prat, a breast cancer researcher, is currently working to identify strategies to tailor treatment for...
Study Examines Breakthrough COVID-19 Infection in Vaccinated Patients With Hematologic Cancers
People with blood cancers are at a higher risk than healthy individuals for severe infection with COVID-19; furthermore, research suggests that they do not always achieve optimal protection from vaccination. A new study published by Pagano et al in the journal Blood—the first to report on...
Expert Point of View: Benjamin Besse, MD
Invited discussant Benjamin Besse, MD, of Gustave Roussy Cancer Center, Villejuif, France, was generally positive about the findings of Impower010 but said that longer-term follow-up of overall survival will be very important. “IMpower010 is the first adjuvant study establishing an immune...
Arginine May Enhance Effectiveness of Radiation Therapy for Brain Metastases
Treatment with arginine, an amino acid, enhanced the effectiveness of radiation therapy in patients with cancer and brain metastases in a proof-of-concept, randomized clinical trial published by Marullo et al in Science Advances. The recently published paper reported the results of administering...
International Medullary Thyroid Carcinoma Grading System: Detecting Adverse Outcomes
In a study reported in the Journal of Clinical Oncology, Xu et al developed a two-tiered international medullary thyroid carcinoma grading system that identifies high-grade disease associated with poorer outcomes. As stated by the investigators, “Currently, there is no widely accepted...
Fear of Side Effects and Lack of Awareness: Barriers to Greater Use of Risk-Reducing Medications for Breast Cancer
A “big problem, maybe the major one,” with risk-reducing medications for breast cancer is low uptake among women at high risk of breast cancer,” Seema A. Khan, MD, told participants at the 2021 Annual Lynn Sage Breast Cancer Symposium.1 Dr. Khan is Professor of Surgery and the Bluhm Family...
Risk-Reducing Medications for Breast Cancer Are Becoming Safer and More Tolerable
Risk-reducing medications for breast cancer may be effective for many women, and recently reported and ongoing trials have led to improvements in their tolerability and safety, Seema A. Khan, MD, reported at the 2021 Annual Lynn Sage Breast Cancer Symposium (virtual).1 Dr. Khan is Professor of...
